Partners of PrEPVacc

The MRC/UVRI & LSHTM Uganda Research Unit, located in Entebbe, Uganda, is an internationally recognized center of excellence for research on HIV infection and related diseases. In 2018, the Unit formally joined the London School of Hygiene and Tropical Medicine (LSHTM).

PrEPVacc’s project leadership is based in Entebbe and oversees the trial database, trial management, and primary laboratory assays.

Professor Pontiano Kaleebu, Director of the Unit, is PrEPVacc’s Chief Investigator and Dr Eugene Ruzagira is Trial Director. Professor Janet Seeley is the Social Science Lead for PrEPVacc and Dr Christian Hansen is Trial Statistician.

If you are a potential participant click here for Masaka site contact details

Imperial College London is a global top ten university with a world-class reputation in science, engineering, business and medicine.

Since 1991, there have been over 15 HIV prevention trials ranging from Phase I to III undertaken at the Imperial Clinical Trial Centre, based at St Mary’s campus, Paddington. Imperial led the application for PrEPVacc’s funding from EDCTP.

Professor Jonathan Weber, Dean of the Faculty of Medicine at Imperial, is PrEPVacc’s Lead Applicant and Coordinator, and Dr Cherry Kingsley is PrEPVacc’s Project Manager, and Product Provider.

The MRC Clinical Trials Unit at UCL, is at the forefront of resolving internationally important questions in infectious diseases and cancer. It carries out challenging and innovative studies, and develops and implements methodological advances in study design, conduct and analysis. It was established in 1998 and is funded by the Medical Research Council, and became part of UCL in 2013.

The Unit has over 30 years’ experience of designing and conducting clinical trials, including HIV therapy, HIV vaccine and vaginal microbicide trials at all phases, and has supported capacity development of clinical trial centres in Mozambique, Tanzania, Uganda and South Africa.

Professor Sheena McCormack is PrEPVacc’s Project Lead.

MRC/UVRI and LSHTM Uganda Research Unit

The MRC/UVRI & LSHTM Uganda Research Unit, located in Entebbe, Uganda, is an internationally recognized center of excellence for research on HIV infection and related diseases. In 2018, the Unit formally joined the London School of Hygiene and Tropical Medicine (LSHTM).

PrEPVacc’s project leadership is based in Entebbe and oversees the trial database, trial management, and primary laboratory assays.

Professor Pontiano Kaleebu, Director of the Unit, is PrEPVacc’s Chief Investigator and Dr Eugene Ruzagira is Trial Director. Professor Janet Seeley is the Social Science Lead for PrEPVacc and Dr Christian Hansen is Trial Statistian.

If you are a potential participant click here for Masaka site contact details

MUHAS is a public university focussed on research and teaching in health and allied sciences, in Dar es Salaam, Tanzania. It is one of the major institutions undertaking health research in Tanzania and has collaborated with Karolinska Instituet I to successfully complete 4 HIV vaccine trials (HIVIS 03, HIVIS-06, TaMoVac-1 and TaMoVac-II) and has extensive experience running Africa-based trials.

Dr Said Aboud is the MUHAS site Principal Investigator and Dr Eligius Lyamuya is a Co-Investigator for the MUHAS site.

If you are a potential participant click here for Dar es Salaam site contact details

NIMR-MMRC is a centre of the National Institute for Medical Research located in Mbeya, Tanzania.

NIMR is the largest public health research institution in Tanzania, and MMRC’s vision is to be an institution of excellence for advancement of health research and development in Tanzania and beyond.

Dr Lucas Maganga is PrEPVacc’s Principal Investigator at NIMR-MMRC.

If you are a potential participant click here for Mbeya site contact details

The Instituto Nacional de Saúde (INS) is the research and public health institute for Mozambique’s Ministry of Health and is very experienced in running vaccine trials.

The INS has three research centres that perform clinical and operational research and PrEPVacc partners with researchers at the Centro de Investigação e Treino em Saúde da Polana Caniço (INS-CISPOC), in Maputo, Mozambique.

Dr Ilesh Jani is Principal Investigator for INS, and Dr Edna Viegas is Principal Investigator for CISPOC.

The Maputo site is part of the Registration Cohort but is not part of PrEPVacc’s clinical trial. Click here for Maputo site contact details

South African Medical Research Council’s HIV and other Infectious Diseases Research Unit is located in Durban, South Africa.

It runs epidemiological, behavioural, basic science and clinical studies that seek to uncover the factors contributing to HIV infection vulnerability.

Its clinical sites for the PrEPVacc study are Phoenix for the Registration Cohort and Verulam for the vaccine trial.

Professor Glenda Gray is PrEPVacc’s National Principal Investigator for SAMRC and Dr Nishanta Singh is Site Principal Investigator.

If you are a potential participant click here for Durban site contact details

Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, in Switzerland is a public non-profit institution dedicated to the improvement of human health through patient care, research and training, providing general hospital needs for the city of Lausanne and its area.

Professor Gepi Pantaleo is PrEPVacc’s Immunologist.

Imperial College London

Imperial College London is a global top ten university with a world-class reputation in science, engineering, business and medicine.

Since 1991, there have been over 15 HIV prevention trials ranging from Phase I to III undertaken at the Imperial Clinical Trial Centre, based at St Mary’s campus, Paddington. Imperial led the application for PrEPVacc’s funding from EDCTP.

Professor Jonathan Weber, Dean of the Faculty of Medicine at Imperial, is PrEPVacc’s Lead Applicant and Coordinator, and Dr Cherry Kingsley is PrEPVacc’s Project Manager, and Product Provider.

Karolinska Instituet, in Stockholm, Sweden, has been instrumental in vaccine research and has long-standing collaborations with MUHAS in Tanzania.

Dr Charlotta Nilsson is an Immunologist for PrEPVacc.

Ludwig Maximilian University of Munich (LMU) was established in 1472 and is one of Germany’s oldest public research Universities.

LMU has had a partnership with the NIMR-Mbeya Medical Research Centre, a PrEPVacc clinical centre, since 1988 and together they have collaborated together on diverse HIV and TB projects.

Dr Arne Kroidl is a clinician and Principal Investigator for PrEPVacc.

International Aids Vaccine Initiative (IAVI) is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV and tuberculosis. It has a 15-year history of capacity building across Africa for HIV vaccine trials. IAVI’s PrEPVacc members are based in Nairobi, Kenya, and in London, UK.

IAVI provides quality assurance and quality control for PrEPVacc and supports its capacity building activities.

Dr Kundai Chinyenze is IAVI’s Principal Investigator for PrEPVacc and Dr Claire Wenden is PrEPVacc’s Lead for Lab Operations.

The Africa Health Research Institute (AHRI) is a multidisciplinary, independent research institute based across two sites in the province of KwaZulu-Natal, South Africa.

AHRI’s goal is to become a source of fundamental discoveries into the susceptibility, transmission and cure of HIV, TB and related diseases

MRC/UVRI and LSHTM Uganda Research Unit

The MRC/UVRI & LSHTM Uganda Research Unit, located in Entebbe, Uganda, is an internationally recognized center of excellence for research on HIV infection and related diseases. In 2018, the Unit formally joined the London School of Hygiene and Tropical Medicine (LSHTM).

PrEPVacc’s project leadership is based in Entebbe and oversees the trial database, trial management, and primary laboratory assays.

Professor Pontiano Kaleebu, Director of the Unit, is PrEPVacc’s Chief Investigator and Dr Eugene Ruzagira is Trial Director. Professor Janet Seeley is the Social Science Lead for PrEPVacc and Dr Christian Hansen is Trial Statistian.

If you are a potential participant click here for Masaka site contact details

Imperial College London

Imperial College London is a global top ten university with a world-class reputation in science, engineering, business and medicine.

Since 1991, there have been over 15 HIV prevention trials ranging from Phase I to III undertaken at the Imperial Clinical Trial Centre, based at St Mary’s campus, Paddington. Imperial led the application for PrEPVacc’s funding from EDCTP.

Professor Jonathan Weber, Dean of the Faculty of Medicine at Imperial, is PrEPVacc’s Lead Applicant and Coordinator, and Dr Cherry Kingsley is PrEPVacc’s Project Manager, and Product Provider.

EuroVacc Foundation, created in 2002, is a non-profit organization based in Amsterdam, The Netherlands, which is dedicated to developing vaccines against infectious diseases, in particular HIV, and to promote world-wide accessibility to these vaccines.

EuroVacc has overseen the GMP manufacturing of vaccine candidates, and will provide the DNA PT123 vaccine for the PrEPVacc trial.

Dr Song Ding is PrEPVacc’s Product Provider.

Gilead is providing Truvada for PrEP in the study.

Dr Jim Rooney and Dr Scott Mcallister are PrEPVacc Product Providers.

GSID is providing AIDSVAX B/E for the vaccine trial.

Dr Carter Lee is PrEPVacc’s Product Provider.

CONRAD is a not-for-profit organisation founded under a cooperative agreement with Eastern Virginia Medical School (EVMS) and USAID and has been the sponsor of late stage HIV prevention studies clinical studies testing Tenofovir gel. 

CONRAD is supporting the PrEPVacc study by providing the point of care urine test kits to the sites to determine PrEP adherence, contributing to protocol development, attending consortium meetings and serving as part of the Trial Management Group.

Dr Gustavo Doncel is the scientific and executive director of CONRAD.